ES2398706T3 - Medio exento de proteínas animales para el cultivo de células - Google Patents
Medio exento de proteínas animales para el cultivo de células Download PDFInfo
- Publication number
- ES2398706T3 ES2398706T3 ES10010584T ES10010584T ES2398706T3 ES 2398706 T3 ES2398706 T3 ES 2398706T3 ES 10010584 T ES10010584 T ES 10010584T ES 10010584 T ES10010584 T ES 10010584T ES 2398706 T3 ES2398706 T3 ES 2398706T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- cells
- hydrolyzate
- medium
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000021120 animal protein Nutrition 0.000 title claims abstract description 80
- 238000004113 cell culture Methods 0.000 title claims abstract description 63
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 141
- 241000700605 Viruses Species 0.000 claims abstract description 139
- 238000004519 manufacturing process Methods 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims description 440
- 239000002609 medium Substances 0.000 claims description 134
- 238000000034 method Methods 0.000 claims description 63
- 210000003501 vero cell Anatomy 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 210000003292 kidney cell Anatomy 0.000 claims description 24
- 210000004962 mammalian cell Anatomy 0.000 claims description 23
- 241000710831 Flavivirus Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 18
- 241000709664 Picornaviridae Species 0.000 claims description 16
- 241000710942 Ross River virus Species 0.000 claims description 16
- 241000700618 Vaccinia virus Species 0.000 claims description 16
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 15
- 241000711573 Coronaviridae Species 0.000 claims description 14
- 210000004102 animal cell Anatomy 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 11
- 241000712461 unidentified influenza virus Species 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 241000700647 Variola virus Species 0.000 claims description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims description 9
- 241000712891 Arenavirus Species 0.000 claims description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 8
- 241000711549 Hepacivirus C Species 0.000 claims description 8
- 241000702263 Reovirus sp. Species 0.000 claims description 8
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 8
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 8
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 8
- 241000710886 West Nile virus Species 0.000 claims description 8
- 241000710772 Yellow fever virus Species 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 229940051021 yellow-fever virus Drugs 0.000 claims description 8
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000991587 Enterovirus C Species 0.000 claims description 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 6
- 241000709721 Hepatovirus A Species 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 241000711386 Mumps virus Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 208000007089 vaccinia Diseases 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 description 127
- 239000006143 cell culture medium Substances 0.000 description 18
- 239000007640 basal medium Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000012258 culturing Methods 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 239000002028 Biomass Substances 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 244000068988 Glycine max Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000004365 Protease Substances 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000036284 oxygen consumption Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000187392 Streptomyces griseus Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 208000037799 influenza C Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- -1 HAMBsF12 Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GKWTZACONBQTNK-IVIZKJKWSA-N N-benzyl-7H-purin-6-amine (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid Chemical compound C(Nc1ncnc2nc[nH]c12)c1ccccc1.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@@]3(CC[C@@H]1O)OC2=O)C(=C)C5.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@]3(OC1=O)C=C[C@@H]2O)C(=C)C5 GKWTZACONBQTNK-IVIZKJKWSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0043—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/74—Undefined extracts from fungi, e.g. yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39424302P | 2002-07-09 | 2002-07-09 | |
| US394243P | 2002-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2398706T3 true ES2398706T3 (es) | 2013-03-21 |
Family
ID=30115698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10010584T Expired - Lifetime ES2398706T3 (es) | 2002-07-09 | 2003-07-08 | Medio exento de proteínas animales para el cultivo de células |
| ES03762657T Expired - Lifetime ES2394085T3 (es) | 2002-07-09 | 2003-07-08 | Medio exento de proteínas animales para el cultivo de células |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03762657T Expired - Lifetime ES2394085T3 (es) | 2002-07-09 | 2003-07-08 | Medio exento de proteínas animales para el cultivo de células |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7955833B2 (enExample) |
| EP (2) | EP2287288B1 (enExample) |
| JP (5) | JP2005532057A (enExample) |
| CN (2) | CN101058800B (enExample) |
| AU (1) | AU2003249990B2 (enExample) |
| CA (1) | CA2491992A1 (enExample) |
| DK (2) | DK2287288T3 (enExample) |
| ES (2) | ES2398706T3 (enExample) |
| MX (1) | MXPA05000418A (enExample) |
| NZ (1) | NZ538094A (enExample) |
| PL (1) | PL214284B1 (enExample) |
| PT (2) | PT2287288E (enExample) |
| SI (1) | SI1520008T1 (enExample) |
| WO (1) | WO2004005493A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| FR2836924B1 (fr) * | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| PT2287288E (pt) | 2002-07-09 | 2012-12-10 | Baxter Int | Meio isento de proteína animal para cultura de células |
| HRP20070474T3 (en) | 2004-03-01 | 2007-11-30 | Ares Trading S.A. | Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells |
| WO2005103235A1 (ja) * | 2004-04-19 | 2005-11-03 | Denka Seiken Co., Ltd. | ウイルスの生産方法 |
| EP2578229B1 (en) * | 2004-09-09 | 2013-07-10 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential iatrogenic risks associated with vaccine antigens |
| US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| AU2011221414B2 (en) * | 2004-10-29 | 2012-09-20 | Takeda Pharmaceutical Company Limited | Animal Protein-Free Media for Cultivation of Cells |
| KR100679112B1 (ko) | 2004-11-17 | 2007-02-07 | 삼성정밀화학 주식회사 | 동물세포 배양방법 |
| CN101189326B (zh) * | 2004-12-23 | 2013-06-12 | 米迪缪尼有限公司 | 用于病毒增殖的非致瘤性mdck细胞系 |
| CA2601006C (en) * | 2005-03-10 | 2012-10-23 | Kyoritsu Seiyaku Corporation | Cell strain capable of being cultured without ingredients derived from animals, method of producing the same, method of producing virus using the same, and method of producing vaccine |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| MX2007012786A (es) * | 2005-04-13 | 2008-01-11 | Merial Ltd | Ensayo para produccion de circovirus porcino. |
| WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| JP2007000077A (ja) * | 2005-06-23 | 2007-01-11 | Hitachi Medical Corp | 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地 |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| WO2007125605A1 (ja) | 2006-04-28 | 2007-11-08 | Kyoritsu Seiyaku Corporation | 動物由来蛋白なしで培養可能な猫の細胞、これを用いたウイルスの生産方法、及びワクチンの生産方法 |
| EA018030B1 (ru) | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| EP2500417A1 (en) * | 2006-08-09 | 2012-09-19 | Vivalis | Method of production of transgenic avian using embryonic stem cells |
| EP2069480B1 (en) * | 2006-09-15 | 2014-03-19 | MedImmune, LLC | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| EP3327132A3 (en) * | 2007-08-09 | 2018-07-18 | Wyeth LLC | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| PL2235197T3 (pl) * | 2007-12-27 | 2018-01-31 | Baxalta GmbH | Sposoby hodowli komórek |
| HUE043863T2 (hu) * | 2007-12-31 | 2019-09-30 | Baxalta GmbH | Lényegében állati fehérjétõl mentes rekombináns furin és eljárás elõállítására |
| KR101220239B1 (ko) * | 2008-04-01 | 2013-01-09 | 바이오스펙트럼 주식회사 | 식물성 펩톤을 포함하는 줄기세포 증식 촉진용 조성물 |
| TW201012930A (en) | 2008-06-16 | 2010-04-01 | Intervet Int Bv | Method of replicating viruses in suspension |
| CN103952376A (zh) | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| WO2011011660A2 (en) * | 2009-07-23 | 2011-01-27 | Xcellerex, Inc. | Drain down and re-feed of microcarrier bioreactor |
| WO2011056591A1 (en) | 2009-10-26 | 2011-05-12 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CN101988047B (zh) * | 2010-05-13 | 2013-07-03 | 维亚生物科技(上海)有限公司 | 一种低成本的昆虫细胞无血清培养基 |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| CN102533634A (zh) * | 2012-02-22 | 2012-07-04 | 江阴剑桥生物技术有限公司 | Cho细胞无血清无蛋白化学培养基 |
| WO2015009743A1 (en) | 2013-07-15 | 2015-01-22 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| GB201321679D0 (en) * | 2013-12-09 | 2014-01-22 | Vibralogics Gmbh | Method of culturing vero cells |
| SG11201605146VA (en) | 2013-12-30 | 2016-07-28 | Baxalta GmbH | A method of predicting a performance characteristic of a plant or yeast hydrolysate and its use |
| ES2909630T3 (es) | 2014-06-04 | 2022-05-09 | Amgen Inc | Métodos de recolección en cultivos de células de mamífero |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| CN105385661B (zh) * | 2014-09-03 | 2019-02-05 | 普莱柯生物工程股份有限公司 | 一种猪圆环病毒2型大规模培养的方法及其应用 |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| CN105154389A (zh) * | 2015-10-15 | 2015-12-16 | 南京三生生物技术有限公司 | 一种适于pk-15细胞生长的低血清无蛋白培养基及其制备方法 |
| WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
| EP3372671B1 (en) * | 2017-03-09 | 2021-11-03 | Evonik Operations GmbH | Culture medium comprising olgopeptides |
| CN107043740A (zh) * | 2017-05-10 | 2017-08-15 | 浙江美保龙生物技术有限公司 | 一种mdbk细胞培养液及其制备方法、使用方法 |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| US12349704B2 (en) | 2018-11-15 | 2025-07-08 | Aleph Farms Ltd. | High quality cultured meat, compositions and methods for producing same |
| CN113330111A (zh) * | 2018-11-21 | 2021-08-31 | 西方溶瘤细胞有限公司 | 病毒的制造 |
| CN113227354A (zh) * | 2019-01-17 | 2021-08-06 | 勃林格殷格翰动物保健美国公司 | 用于禽类疫苗生产的无血清培养基及其用途 |
| JP2022527235A (ja) | 2019-01-23 | 2022-06-01 | 義裕 河岡 | インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異 |
| WO2020153619A1 (ko) * | 2019-01-25 | 2020-07-30 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| IL322673A (en) | 2019-12-31 | 2025-10-01 | Air Protein Inc | High-protein food compositions |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| CN115244171A (zh) * | 2020-01-24 | 2022-10-25 | 空气蛋白公司 | 微生物来源的蛋白质水解物以及其制备方法和用途 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| MY204715A (en) * | 2020-11-12 | 2024-09-10 | Imu Education Sdn Bhd | Culture medium for bacteria |
| KR102581772B1 (ko) * | 2021-03-30 | 2023-09-22 | 강원대학교 산학협력단 | 식물 및 곤충 단백질 가수 분해물을 이용한 배양육 제조를 위한 최적 배양 방법 및 그 응용 |
| EP4531878A1 (en) * | 2022-06-03 | 2025-04-09 | Bluerock Therapeutics LP | Cell delivery vehicle and methods of using the same |
| CN120359291A (zh) * | 2024-05-27 | 2025-07-22 | 安琪酵母股份有限公司 | 一种以蛋白水解物为核心原料的干细胞培养基制备及其应用方法 |
| CN119162122B (zh) * | 2024-09-14 | 2025-10-03 | 江苏华诺泰生物医药科技有限公司 | 一种流感病毒维持液配方及其制备方法和应用 |
| CN120738314A (zh) * | 2025-09-08 | 2025-10-03 | 安琪酵母股份有限公司 | 一种无动物源复合蛋白水解物及其制备方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT165999B (de) | 1947-06-26 | 1950-05-25 | Delle Atel Const Electr | Einirchtung zum Schutz von Drehstrommotoren gegen Überstrom |
| FR2196386A1 (en) | 1972-08-17 | 1974-03-15 | Cudennec Alain | Culture media selection - for identification of unknown bacteria |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
| US4282315A (en) * | 1979-09-13 | 1981-08-04 | Corning Glass Works | Preparation of enriched whole virus radioligand |
| US4443540A (en) | 1980-05-09 | 1984-04-17 | University Of Illinois Foundation | Protein hydrolysis |
| DK207980A (da) | 1980-05-13 | 1981-11-14 | Novo Industri As | Fremgangsmaade til fremstilling af et skumnings- eller emulgeringsmiddel paa sojaproteinbasis |
| DE3122669A1 (de) * | 1980-06-12 | 1982-02-11 | Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| CH652378A5 (de) | 1983-12-21 | 1985-11-15 | Heinrich Nagel Ag Wislikofen | Einrichtung zum absaugen und zerkleinern von in einem gasfoermigen medium foerderbarem material. |
| FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| EP0217822B1 (en) | 1985-02-13 | 1993-05-12 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
| US4978616A (en) | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
| JP2520681B2 (ja) | 1986-08-04 | 1996-07-31 | ザ ユニバーシティ オブ ニュー サウス ウェールズ | 生合成のヒトの成長ホルモン製品 |
| US4710282A (en) | 1986-08-08 | 1987-12-01 | Maryan Chak | Device for siliverizing running water |
| JPH03500529A (ja) * | 1987-06-18 | 1991-02-07 | モナシュ ユニバーシティ | 増殖因子 |
| WO1989000192A1 (en) | 1987-06-30 | 1989-01-12 | Amgen Inc. | Production of kallikrein |
| JP2507882B2 (ja) | 1988-02-17 | 1996-06-19 | 工業技術院長 | 外部増殖因子非依存性増殖良好細胞株の製造法 |
| JPH01211878A (ja) | 1988-02-19 | 1989-08-25 | Fujitsu Ltd | Ｉ／ｏピンの修復方法 |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5573937A (en) | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| WO1991010726A1 (en) | 1990-01-22 | 1991-07-25 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Co-independent growth medium for maintenance and propagation of cells |
| JP2844484B2 (ja) | 1990-02-22 | 1999-01-06 | 味の素株式会社 | 組換え蛋白質の生産方法 |
| JP2859679B2 (ja) | 1990-03-01 | 1999-02-17 | 協和醗酵工業株式会社 | 新規細胞株 |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| US5378612A (en) | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| JPH04228066A (ja) | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | 外来遺伝子発現用培養細胞 |
| US5213795A (en) * | 1990-10-24 | 1993-05-25 | Oxford | Encephalomyocarditis virus vaccine |
| EP0531562A1 (de) | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
| JPH05123178A (ja) | 1991-11-01 | 1993-05-21 | Ajinomoto Co Inc | Ｌ−フエニルアラニンの製造法 |
| JP3511399B2 (ja) * | 1993-03-31 | 2004-03-29 | 株式会社三菱化学ヤトロン | 細胞培養基材及び細胞培養方法 |
| AU7895898A (en) | 1993-04-26 | 1998-10-08 | Hans Wolf | Mammal cell lines and method of obtaining glycoproteins |
| DE4313620A1 (de) | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
| US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
| JP4098372B2 (ja) | 1993-07-28 | 2008-06-11 | 三菱化学株式会社 | ヘパリン結合性増殖因子の生産方法 |
| JP2766165B2 (ja) | 1993-08-02 | 1998-06-18 | 株式会社バイオポリマー・リサーチ | バクテリアセルロースの製造方法 |
| US5833162A (en) * | 1993-12-22 | 1998-11-10 | Daewoo Electronics Co., Ltd. | Reel table driving device for a video cassette recorder |
| US5719050A (en) | 1993-12-24 | 1998-02-17 | Eiken Chemical Co., Ltd. | Animal cell culturing media containing N-acetyl-L-glutamic acid |
| EP0666312A1 (en) | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
| US5789247A (en) | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
| WO1996007730A2 (de) | 1994-09-09 | 1996-03-14 | Renner Wolfgang A | Chemisches verfahren zur förderung der proliferation von tierischen zellen |
| ES2323490T3 (es) | 1994-11-10 | 2009-07-17 | Baxter Healthcare Sa | Procedimiento de produccion de agentes biologicos en un medio de cultivo sin proteinas. |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| AT403167B (de) | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
| JP3244391B2 (ja) | 1994-12-08 | 2002-01-07 | 財団法人国際超電導産業技術研究センター | 複合基板及びそれを用いた単結晶基板の製造方法 |
| WO1996018734A1 (en) | 1994-12-16 | 1996-06-20 | Novartis Ag | Production of recombinant secretory component |
| EP0811056B1 (en) | 1995-02-23 | 2000-05-31 | Quest International B.V. | Peptides for tissue and cell culture media |
| US5741705A (en) | 1995-02-23 | 1998-04-21 | Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. | Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides |
| AU6125396A (en) | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
| CA2223484A1 (en) | 1995-06-07 | 1996-12-19 | Thomas Jefferson University | Anti-fungal agents and methods of identifying and using the same |
| AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| EP2243827B2 (en) | 1996-08-30 | 2017-11-22 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| AU4751697A (en) * | 1996-10-10 | 1998-05-05 | Douglas Danner | Animal cell culture media comprising plant-derived nutrients |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| EP2267113B1 (en) | 1997-05-28 | 2013-07-17 | Novartis AG | Culture medium for Neisseria meningitidis with soy bean extract as amino acid source and no protein complexes of animal origin |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| ATE341625T1 (de) | 1997-07-23 | 2006-10-15 | Roche Diagnostics Gmbh | Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren |
| JPH11211488A (ja) | 1998-01-21 | 1999-08-06 | Matsushita Electric Ind Co Ltd | 携帯情報端末を用いたデータ転送システム |
| FR2775983B1 (fr) | 1998-03-13 | 2000-11-10 | Pasteur Merieux Serums Vacc | Milieu et procede de propagation et de multiplication virales |
| WO1999057246A1 (en) | 1998-05-01 | 1999-11-11 | Life Technologies, Inc. | Animal cell culture media comprising non-animal or plant-derived nutrients |
| US6406909B1 (en) * | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| EP1200561B1 (de) | 1999-08-05 | 2006-06-14 | Baxter Aktiengesellschaft | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
| NZ529329A (en) | 1999-08-25 | 2005-06-24 | Immunex Corp | Compositions and methods for improved cell culture |
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| JP2001211878A (ja) * | 2000-02-04 | 2001-08-07 | National Federation Of Dairy Cooperative Associations | ヨーグルトスターター乳酸菌の高濃度培養方法、及び得られた高濃度培養液を用いたヨーグルトの製造方法 |
| US7494659B2 (en) | 2000-09-25 | 2009-02-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Live attenuated influenza vaccine |
| EP1208966A1 (en) | 2000-11-27 | 2002-05-29 | Cheng-Kun Liao | Manufacturing process of patio tabletop glass with broken protection |
| PT2287288E (pt) | 2002-07-09 | 2012-12-10 | Baxter Int | Meio isento de proteína animal para cultura de células |
| JP4316484B2 (ja) | 2004-12-10 | 2009-08-19 | シャープ株式会社 | 画像形成装置、トナー濃度制御方法、トナー濃度制御プログラムおよびその記録媒体 |
-
2003
- 2003-07-08 PT PT100105840T patent/PT2287288E/pt unknown
- 2003-07-08 CA CA 2491992 patent/CA2491992A1/en not_active Abandoned
- 2003-07-08 US US10/614,037 patent/US7955833B2/en not_active Expired - Lifetime
- 2003-07-08 ES ES10010584T patent/ES2398706T3/es not_active Expired - Lifetime
- 2003-07-08 DK DK10010584T patent/DK2287288T3/da active
- 2003-07-08 EP EP20100010584 patent/EP2287288B1/en not_active Expired - Lifetime
- 2003-07-08 CN CN2007101019058A patent/CN101058800B/zh not_active Expired - Lifetime
- 2003-07-08 PL PL374782A patent/PL214284B1/pl unknown
- 2003-07-08 MX MXPA05000418A patent/MXPA05000418A/es active IP Right Grant
- 2003-07-08 NZ NZ538094A patent/NZ538094A/en not_active IP Right Cessation
- 2003-07-08 ES ES03762657T patent/ES2394085T3/es not_active Expired - Lifetime
- 2003-07-08 CN CN03821326A patent/CN100591759C/zh not_active Expired - Lifetime
- 2003-07-08 SI SI200332208T patent/SI1520008T1/sl unknown
- 2003-07-08 AU AU2003249990A patent/AU2003249990B2/en not_active Expired
- 2003-07-08 EP EP20030762657 patent/EP1520008B1/en not_active Expired - Lifetime
- 2003-07-08 WO PCT/EP2003/007341 patent/WO2004005493A1/en not_active Ceased
- 2003-07-08 DK DK03762657T patent/DK1520008T3/da active
- 2003-07-08 JP JP2004518745A patent/JP2005532057A/ja not_active Withdrawn
- 2003-07-08 PT PT03762657T patent/PT1520008E/pt unknown
-
2010
- 2010-11-29 JP JP2010265835A patent/JP5485863B2/ja not_active Expired - Lifetime
-
2011
- 2011-05-06 US US13/102,765 patent/US8524497B2/en not_active Expired - Fee Related
- 2011-11-25 JP JP2011258106A patent/JP6084359B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-10 JP JP2013100500A patent/JP6178109B2/ja not_active Expired - Lifetime
- 2013-08-06 US US13/960,481 patent/US9163211B2/en not_active Expired - Lifetime
-
2014
- 2014-12-03 JP JP2014245252A patent/JP6244294B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2398706T3 (es) | Medio exento de proteínas animales para el cultivo de células | |
| ES2393317T5 (en) | Animal protein-free media for cultivation of cells | |
| ES2488818T3 (es) | Método para la producción a gran escala de virus | |
| DK1974014T3 (en) | OLIGOPEPTID-FREE CELL CULTURE MEDIA | |
| HK1083635B (en) | Animal protein free media for cultivation of cells | |
| HK1108713B (en) | Animal protein free media for cultivation of cells |